tbuckley/cabot-search huggingface dataset:
AB0841 Assessment of relationship between loneliness, perceived social support, depression and medication adherence in ankylosing spondylitis patients
Authors: E. Öksüz, F.I. Cinar, M. Cinar, E. Tekgoz, S. Yilmaz
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Ankylosing spondylitis (AS) is a chronic, progressive, inflammatory disease which can cause labour loss and deformities and requiring long-term treatment. Loneliness, perceived social support, depression, patients' beliefs about medicines and treatment may affect their medication adherence and treatment success. <h3>Objectives</h3> In this study, we aimed to investigate the relationship between loneliness, perceived social support, depression and medication adherence in AS patients. <h3>Methods</h3> This cross-sectional study was conducted in a tertiary rheumatology outpatient clinic. One hundred and nineteen AS patients were enrolled to the study. The socio-demographic and clinical features of the patients agreeing to participate were recorded to the "Patient Assessment Form". The patients' disease activity and functional status were determined with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI, and the Bath Ankylosing Spondylitis Functional Index (BASFI), respectively. The pain and global assessment of the patients' were assessed with a numerical visual analogue scale (nVAS; 0–10 cm). The medication adherence of the patients was assessed with the Morisky Green Levine Scale (MGLS). The UCLA Loneliness Scale, the Multidimensional Scale of Perceived Social Support (MSPSS) and the Beck Depression Inventory (BDI) were used to determine loneliness, perceived social support, and depression of the patients. <h3>Results</h3> One hundred five patients (88.2%) were male, the mean age was 35.80±9.08 years, and the mean disease duration was 9.88±6.34 years. The mean BASDAI, BASFI and patient global assessment scores were; 4.57±2.63, 3.23±2.76, and 4.13±3.23, respectively. According to the MGLS medication adherence groups, patients with low medication adherence had higher BASDAI, spinal pain, spinal pain at night, fatigue and patient global assessment scores and had lower mean ages (p&lt;0.05). Among the MGLS medication adherence groups, patients with low medication adherence had lower MSPSS scores, and had higher UCLA Loneliness Scale and Beck Depression Inventory scores (p=0.037, p&lt;0.001, p=0.022, respectively) (table 1). <h3>Conclusions</h3> In this study, it was shown that as the average age and social support scores of patients decreased, and as the BASDAI, spinal pain, spinal pain at night, fatigue, patient global assessment, loneliness and depression scores increased, adherence to treatment were decreased. It is thought that patients should be handled holistically in terms of biopsychosocial aspect in order to improve adherence to medical treatment. <h3>Disclosure of Interest</h3> None declared
AIP, Jo-1 and ECMO
Authors: Anitha Vijayasingam, Inmaculada Alcalde, Sachin Shah, Ben Singer, Anthony Bastin, Ian Chikanza, Jeremy Cordingley, Gavin Thomas
Journal: Thorax (2018)

A 56-year-old woman of South Indian origin presented with 2 weeks of cough, fever, malaise and dyspnoea ,with no response to amoxicillin. She was generally well with mild hypertension, type 2 diabetes controlled with metformin, hypothyroidism and vitamin D deficiency. There were no other relevant exposures, previous imaging, lung function or other investigations.

Initial observations: temperature 38.2°C, blood pressure 112/76 mm Hg, RR 24, SpO2 94% on 3 L/min of O2 via nasal cannulae. Examination of the chest revealed bilateral crackles.

Chest X-ray on admission showed bilateral patchy consolidation to the mid zones (figure 1A).



Figure 1 
Radiology on admission, initiation of mechanical ventilation, initiation of ECMO, and discharge.



Initial test results are shown below:

White cell count 8.8×109/L (4–10).

C-reactive protein 141 (<5).

HIV negative.

Throat swab PCR negative for respiratory viruses.

With a working diagnosis of community-acquired pneumonia, treatment was initiated promptly with intravenous amoxicillin/clavulanic acid and clarithromycin, O2 via nasal cannulae, intravenous crystalloids and paracetamol, and the patient was admitted to the acute admissions unit. Despite this, the patient failed to improve. Amoxicillin/clavulanic acid was changed to piperacillin/tazobactam, and she was transferred to the high dependency unit (HDU) 4 days after admission due to increasing O2 requirements. Sputum examination was positive for Candida sp only.

This patient deteriorated despite appropriate medical therapy. She was initially managed on HDU with high flow nasal O2. However, her respiratory failure progressed rapidly, requiring invasive mechanical ventilation 5 days after admission. CT scan of the chest showed features consistent with ARDS (Acute Respiratory Distress Syndrome) (figure 1B).

There was little change over the following 4 days despite treatment with meropenem, clarithromycin and fluconazole. Ten days after admission, on day 5 of mechanical ventilation, gas exchange and lung mechanics rapidly deteriorated with a severe hypoxaemic respiratory acidosis (FiO2 …
AB1106 Depression and anxiety in paediatricsystemic lupus erythematosus. a systematic review
Authors: M.C. Quilter, D. Korczak
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Depression and anxiety are common and treatable childhood mental health disorders that have been reported to impact outcomes for individuals with childhood-onset Systemic Lupus Erythematosus (cSLE)<sup>1</sup>. Research into the prevalence of depression/anxiety and cSLE comorbidity has reported conflicting results, and to our knowledge, no previous review of these data has been undertaken. <h3>Objectives</h3> To synthesise current knowledge regarding the association of depression and anxiety disorders with cSLE among paediatric patients. <h3>Methods</h3> Studies were identified through a comprehensive search of MEDLINE, EMBASE, PsychINFO, LILACS and Web Of Science (from database inception – July 2017) using MESH headings and Keywords for 'lupus erythematosus', and 'depression' or 'anxiety'. Included studies measured depression and/or anxiety symptoms prospectively among children and youth 8 to 21 years of age with a diagnosis cSLE. Data were extracted by two independent coders and where discrepancies occurred, agreement was reached by consensus. <h3>Results</h3> Sixty-two studies met criteria for full text review, and of these, 13 studies were included in the final analysis. The majority (80%) of studies were of cross-sectional design, with sample sizes ranging from 14 to 100 (mean=47) participants. The mean age of participants was 15.6 years and participants were predominantly female. Prevalence rates for depression ranged from 6.7% to 54%. Anxiety symptom prevalence was 20% to 34%. All studies employed self-report instruments to assess depression and anxiety; none of the studies utilised semi-structured diagnostic interview to make psychiatric diagnoses. Significant heterogeneity precluded meta-analysis of the data. <h3>Conclusions</h3> Depression and anxiety may be common comorbidities of cSLE however current research is limited by a paucity of studies, small sample sizes and an inability to confirm psychiatric diagnoses. Future research addressing these limitations is needed. <h3>Reference</h3> [1] Kohut SA, Williams T, Jayanthikumar J, Landolt-Marticorena C, Lefebvre A, Silverman E, Levy D: Depressive symptoms are prevalent in childhood-onset systemic lupus erythematosus (cSLE). Lupus2013, 22(7):712–720 <h3>Disclosure of Interest</h3> None declared
Textural analysis demonstrates heterogeneous [<sup>18</sup>F]-fluorodeoxyglucose uptake in radiologically normal lung in patients with idiopathic pulmonary fibrosis
Authors: Shamsuddeen A. Aliyu, Ged Avery, Christopher Cawthorne, Stephen J. Archibald, Timor Kadir, Julien M.Y. Willaime, Alyn H. Morice, Simon P. Hart, Michael G. Crooks
Journal: European Respiratory Journal (2018)

<b>Textural analysis demonstrates increased heterogeneity of [<sup>18</sup>F]-FDG uptake in normal lung (on CT) in patients with IPF. Molecular imaging of the lungs using PET can be used to study early disease in IPF before CT abnormalities are apparent.</b>http://ow.ly/T82W30lGU0X
Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials
Authors: Ravi B. Patel, Sanjiv J. Shah
Journal: The Annual Review of Pharmacology and Toxicology (2018)

Heart failure with preserved ejection fraction (HFpEF) accounts for over half of prevalent heart failure (HF) worldwide, and prognosis after hospitalization for HFpEF remains poor. Due, at least in part, to the heterogeneous nature of HFpEF, drug development has proved immensely challenging. Currently, there are no universally accepted therapies that alter the clinical course of HFpEF. Despite these challenges, important mechanistic understandings of the disease have revealed that the pathophysiology of HFpEF is distinct from that of HF with reduced ejection fraction and have also highlighted potential new therapeutic targets for HFpEF. Of note, HFpEF is a systemic syndrome affecting multiple organ systems. Depending on the organ systems involved, certain novel therapies offer promise in reducing the morbidity of the HFpEF syndrome. In this review, we aim to discuss novel pharmacotherapies for HFpEF based on its unique pathophysiology and identify key research strategies to further elucidate mechanistic pathways to develop novel therapeutics in the future.
Abstract 17340: High Fat Diet Exacerbates Uridine Adenosine Tetraphosphate (Up4A)-Mediated Decrease in Coronary Flow in Atherosclerotic ApoE Knockout Mice: Role of Purinergic P2X1 Receptors
Authors: ZHICHAO ZHOU, Bunyen Teng, Hicham Labazi, Changyan Sun, Yan Yang, Xiaorong Zeng, S. Jamal Mustafa
Journal: Circulation (2015)

Introduction: Up4A, a novel endothelium-derived vasoactive agent, is proposed to play a role in cardiovascular disorder via activation of P2 receptors (P2R). Here, we evaluated the vasoactive effect of Up4A on coronary flow (CF) in ApoE knockout mice (KO) with and without high fat diet (HFD). Methods: Functional studies were conducted in isolated mouse hearts using Langendorff and isolated coronary arteries (diameter≈100 μm) using wire Myograph. Immunofluorescence was performed for P2X1R expression in isolated coronary arteries. Results: There was no significant difference in baseline CF (ml/min/g) among wild type (WT, 18.4±0.5), ApoE KO (17.6±1.1) and ApoE KO+HFD (15.9±1.0). Infusion of Up4A (10-9-10-5 M) resulted in a dose-dependent reduction in CF in WT (by ~38%), which was similar to ApoE KO (by ~40%). In isolated coronary arteries of WT, Up4A produced a mild contraction up to ~20%, indicating a vasoconstrictor effect of Up4A. Notably, Up4A further decreased CF in ApoE+HFD as compared to ApoE. Moreover, selective P2X1R antagonist MRS2159 (10 μM) restored Up4A-mediated decrease in CF more in ApoE+HFD than ApoE (Figure). Finally, the percentage expression of vasoconstrictor P2X1R on smooth muscle cells (SMC) of coronary arteries was higher in ApoE+HFD than ApoE, which was due to a markedly reduced vasodilator P2X1R expression on EC in ApoE+HFD (8.7±0.6 fluorescence intensity in A.U.) than ApoE (22.1±0.5), while P2X1R expression on SMC was similar between ApoE+HFD (6.3±0.4) and ApoE (8.4±0.3). Conclusion: Up4A exerts a vasoconstrictor influence in mouse coronary microcirculation. Up4A decreases CF in WT to a similar extent in ApoE, whereas HFD exacerbates Up4A-decreased CF in ApoE possibly through downregulation of vasodilator P2X1R on EC. These findings indicate that Up4A alters CF in atherosclerosis and P2X1R may represent a potential therapeutic target.
Hyperprogression during nivolumab (Nivo) or irinotecan (IRI) as salvage-line in patients with metastatic gastric cancer
Authors: Naotoshi Sugimoto, Toshiyuki Ohtsuka, Koto Fujiishi, Akira Kusakabe, Akiko Hasegawa, Minako Nishio, Fumie Fujisawa, Toshinari Yagi, Fumio Imamura
Journal: Annals of Oncology (2018)
GW29-e1731 Predictive Value of Vascular Response to Cuff Inflation–Induced Pain in the Control Arm for Adverse Cardiovascular Events
Authors: Tao Sun, Ryan J. Lennon, Robert J. Widmer, Joerg Hermann, Zhang Ming, Zhi Liu, Shi Wei Yang, Kyung Hwa Park, Lilach O. Lerman, Amir Lerman
Journal: Journal of the American College of Cardiology (2018)
FRI0098 The incidence and clinical characteristics of mycobacterium tuberculosis infection among sle and ra patients in korea
Authors: T Kim, J Yun, D Yoo, J Jun, S Jung, I Lee, S Bae, S Kim
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> A prevalence rate in a general population estimated by chest x-ray was reported 1.03% in 1995. <h3>Objectives</h3> The aim of this study was to describe the incidence and clinical characteristics of M. tuberculosis infection among SLE and RA patients in Korea. <h3>Methods</h3> We assessed retrospectively 283 SLE and 284 RA patients with median disease duration of 6 years and 9 years, respectively. <h3>Results</h3> Tuberculosis was documented from 15 SLE and 7 RA patients with the incidence rate of 7.9/1,000 patient-years and 2.3/1,000 patient-years, respectively (p &lt; 0.05). SLE-associated tuberculosis included 3 miliary tuberculosis, 7 pulmonary tuberculosis (including 1 diffuse pulmonary involvement with meningitis) predominantly involved in mid-/lower lung field more than 2 lobes, and 5 extra-pulmonary forms (2 osteomyelitis, renal tuberculosis, laryngeal tuberculosis, pleurisy). Four out of seven pulmonary tuberculosis were relapsed cases even after adequately treated. All RA-associated tuberculosis were a pulmonary tuberculosis and most of them were localised to one lobe, and also only 1 case was relapsed. All patients were successfully treated except for two died of miliary tuberculosis. A history of high dose steroid or cytotoxic drugs and any organ involvement were not related to the development of tuberculosis. SLE-associated tuberculosis was developed 48.13 ¢®¨ú35.14 months after their initial symptom and 20.87 ¢®¨ú23.53 months after clinical diagnosis. <h3>Conclusion</h3> Taken together characteristics of tuberculosis in SLE patients are; 1) a higher incidence rate, 2) more frequent extra-pulmonary involvements, 3) more extensive pulmonary involvements 4) a higher relapse rate (Odds ratio 4.14). Thus, the contributory role of M. tuberculosis infection in the morbidity and mortality of patients with SLE must be emphasised, especially in areas endemic for M. tuberculosis. <h3>References</h3> Segal BH, Sneller MC. Infectious complications of immunosuppressive therapy in patients with rheumatic diseases. Rheum Dis Clin North Am. 1997;23:219–37 Petri M. Infection in systemic lupus erythematosus. Rheum Dis Clin North Am. 1998;24:423–56 Victorio-Navarra STG, Dy EER, Arroyo CG, Torralba TP. Tuberculosis among Filipino patients with systemic lupus erythematosus. Semin Arthritis Rheum. 1996;26:628–34 Kim HA, Yoo CD, Baek HJ, <i>et al</i>. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease paient population. Clin Exp Rheumatol. 1998;16:9–13 Kim SJ, Hong YP, Lew WJ, Yang SC, Lee EG. Incidence of pulmonary tuberculosis in Korean civil servants. Tuber Lung Dis. 1995;76:534–9
Evaluation of rectal swab use for the determination of enteric pathogens: a prospective study of diarrhoea in adults
Authors: T. Kotar, M. Pirš, A. Steyer, T. Cerar, B. Šoba, M. Skvarc, M. Poljšak Prijatelj, T. Lejko Zupanc
Journal: Clinical Microbiology and Infection (2018)
Prolonged treatment with Tadekinig alfa in adult-onset Still’s disease
Authors: Uta Kiltz, David Kiefer, Jürgen Braun, Eduardo Jorge Schiffrin, Charlotte Girard-Guyonvarc'h, Cem Gabay
Journal: Annals of the Rheumatic Diseases (2018)

Adult-onset Still’s disease (AOSD) is a rare systemic autoinflammatory disease, the treatment of which is still not well defined. Biological disease modifying antirheumatic drugs (bDMARDs), including interleukin (IL)-1 and IL-6 antagonists are used empirically in patients refractory to conventional DMARDs.1 This 12-week open-label clinical trial with Tadekinig (recombinant IL-18 binding protein, IL-18BP) showed promising results.2 Herein, we report two patients with AOSD treated successfully with Tadekinig during several months.

Case 1 . A 50-year-old patient was diagnosed with AOSD in August 2014 when presenting with arthritis, recurrent fever episodes, sore throat and skin rash. C reactive protein (CRP, 22.9 mg/dL) and ferritin (3568 ng/mL) levels were markedly elevated. Since the initial treatment with prednisolone starting with 100 mg/day and oral methotrexate (MTX) 15 mg/week was insufficient, anakinra was started with 100 mg sc/day and MTX dose was augmented to 25 mg sc/week. High disease activity persisted and prednisolone tapering below 15 mg/day was impossible. As a side effect …
Prognostic implications of mismatch repair deficiency in patients with early-stage colorectal and endometrial cancer
Authors: E. Fountzila, V. Kotoula, G. Pentherdoudakis, K. Manousou, E. Vrettou, C. Poulios, C. Papadimitriou, G. Raptou, E. Pectasides, G. Polychronidou, G. Karayannopoulou, S. Chrisafi, P. Papakostas, T. Makatsoris, A. Psyrri, E. Samantas, M. Bobos, C. Christodoulou, D.G. Pectasides, G. Fountzilas
Journal: Annals of Oncology (2018)
Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial
Authors: Damien Subtil, Gilles Brabant, Emma Tilloy, Patrick Devos, Frédérique Canis, Annie Fruchart, Marie-Christine Bissinger, Jean-Charles Dugimont, Catherine Nolf, Christophe Hacot, Sophie Gautier, Jérôme Chantrel, Marielle Jousse, David Desseauve, Jean Louis Plennevaux, Christine Delaeter, Sylvie Deghilage, Anne Personne, Emmanuelle Joyez, Elisabeth Guinard, Eric Kipnis, Karine Faure, Bruno Grandbastien, Pierre-Yves Ancel, François Goffinet, Rodrigue Dessein
Journal: The Lancet (2018)
Abstract 15044: Oxygen Uptake at Aerobic Thresholds During Exercise Testing, Cardiovascular and All-Cause Mortality Outcomes
Authors: Setor K Kunutsor, Hassan Khan, Francesco Zaccardi, Rainer Rauramaa, Jari A Laukkanen
Journal: Circulation (2016)

Introduction: Cardiorespiratory fitness (CRF) is independently and inversely associated with cardiovascular outcomes. Oxygen uptake (VO2) at aerobic thresholds, which can be defined at submaximal e...
Magnetic Resonance Imaging–Based Prediction of Prostate Cancer Risk
Authors: Giampaolo Bianchi, Maria Chiara Sighinolfi, Bernardo Rocco
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Clinical impact of hypothyroidism and PD-L1 SNPs in patients with non-small cell lung cancer treated with nivolumab
Authors: T. Yamamoto, T. Nomizo, H. Ozasa, T. Tsuji, Y. Yasuda, H. Yoshida, Y. Sakamori, T. Hirai, Y.H. Kim
Journal: Annals of Oncology (2018)
Management of locoregional recurrence after radical resection of a primary non-metastatic retroperitoneal soft tissue sarcoma: Results of a retrospective series in a tertiary care center
Authors: C. Honoré, M. Faron, O. Mir, L. Haddag, S. Dumont, P. Terrier, J. Adam, C. Lepéchoux, A. Le Cesne
Journal: Annals of Oncology (2018)
RNA-based analysis of anaplastic lymphoma kinase (ALK) fusions in non-small cell lung cancer (NSCLC) cases showing immunohistochemistry/fluorescence in-situ hybridisation (IHC/FISH) discordance
Authors: C. Vollbrecht, D. Lenze, M. Hummel, A. Lehmann, M. Moebs, N. Frost, P. Jurmeister, L. Schweizer, U. Kellner, M. Dietel, M. von Laffert
Journal: Annals of Oncology (2018)
GW29-e1986 Inhibition of miR-22-3p Suppresses Hyperlipidemia-induced Endothelial Progenitor Cells Senescence via Targeting Vasohibin-1.
Authors: Jiang He, Wenhao Xia, Bingbo Yu, Xinzhu Tong, Yijia Shao, Jun Tao
Journal: Journal of the American College of Cardiology (2018)
Response to Open Peer Commentaries on “The Ethics of Smart Pills and Self-Acting Devices: Autonomy, Truth-Telling, and Trust at the Dawn of Digital Medicine”
Authors: Craig M. Klugman, Laura B. Dunn, Jack Schwartz, I. Glenn Cohen
Journal: The American Journal of Bioethics (2018)

We thank all of the insightful authors who wrote open peer commentaries to further the conversation about digital medicine that we raised in our article, “The Ethics of Smart Pills and Self-Acting ...
P3.CR-02 SBRT of Lung Primary After Complete Resolution of Metastatic Disease in Case of EGFR Mutated Adenocarcinoma Lung: A Case Report
Authors: S. Majumdar, S. Dhar, S. Mishra, S. Patra, S. Mohakud, P. Mohapatra, D. Parida
Journal: Journal of Thoracic Oncology (2018)
Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes
Authors: Francesca Porcellati, Paola Lucidi, Paola Candeloro, Patrizia Cioli, Anna Marinelli Andreoli, Gianluca Curti, Geremia B. Bolli, Carmine G. Fanelli
Journal: Diabetes Care (2018)

This study characterized the pharmacokinetics (PK), pharmacodynamics (PD), and endogenous (hepatic) glucose production (EGP) of clinical doses of glargine U300 (Gla-300) and glargine U100 (Gla-100) under steady-state (SS) conditions in type 1 diabetes mellitus (T1DM).T1DM subjects (N = 18, age 40 ± 12 years, T1DM duration 26 ± 12 years, BMI 23.4 ± 2 kg/m2, A1C 7.19 ± 0.52% [55 ± 5.7 mmol · mol-1-1]) were studied after 3 months of Gla-300 or Gla-100 (evening dosing) titrated to fasting euglycemia (random, crossover) with the euglycemic clamp using individualized doses (Gla-300 0.35 ± 0.08, Gla-100 0.28 ± 0.07 units · kg-1).Plasma free insulin concentrations (free immunoreactive insulin area under the curve) were equivalent over 24 h with Gla-300 versus Gla-100 (point estimate 1.11 [90% CI 1.03; 1.20]) but were reduced in the first 6 h (0.91 [90% CI 0.86; 0.97]) and higher in the last 12 h postdosing (1.38 [90% CI 1.21; 1.56]). Gla-300 and Gla-100 both maintained 24 h euglycemia (0.99 [90% CI 0.98; 1.0]). The glucose infusion rate was equivalent over 24 h (1.03 [90% CI 0.88; 1.21]) but was lower in first (0.77 [90% CI 0.62; 0.95]) and higher (1.53 [90% CI 1.23; 1.92]) in the second 12 h with Gla-300 versus Gla-100. EGP was less suppressed during 0-6 h but more during 18-24 h with Gla-300. PK and PD within-day variability (fluctuation) was 50% and 17% lower with Gla-300.Individualized, clinical doses of Gla-300 and Gla-100 resulted in a similar euglycemic potential under SS conditions. However, Gla-300 exhibited a more stable profile, with lower variability and more physiological modulation of EGP compared with Gla-100.